Should all children with asthma be treated with antileukotrienes – a review of clinical trials

Paweł Majak; Iwona Stelmach

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2009
vol. 26

Send email

Copy url:

abstract:

Should all children with asthma be treated with antileukotrienes – a review of clinical trials

Paweł Majak

,

Iwona Stelmach

Post Dermatol Alergol 2009; XXVI, 5: 313–314

Online publish date: 2009/10/19

View full text Get citation

In the treatment of persistent asthma, randomized controlled trials have shown leukotriene inhibitors to be more effective than placebo but less effective than inhaled corticosteroids. The use of leukotriene inhibitors has shown an inhaled-steroid-sparing effect, a reduction in need for systemic steroid treatment, or cost savings. In the light of the results of our study montelukast seems to be the best therapeutic option for exercise-induced asthma. Interestingly, montelukast may have some preventive activity against viral-induced asthma exacerbations. There is strong evidence for clinical effectiveness of montelukast in all asthma phenotypes, which makes this drug the most universal anti-asthma treatment option. As established for all drugs commonly used in the treatment of asthma, there is individual variability also in response to montelukast. Therefore, the therapeutic decision in each case should be associated with calculation of the risk/benefit ratio.

keywords:

Should all children with asthma be treated with antileukotrienes – a review of clinical trials

Paweł Majak , Iwona Stelmach

asthma, montelukast

Paweł Majak

,

Iwona Stelmach